PharmiNews

Directory of Pharma Companies and News

Company Profile

Gyroscope Therapeutics

Gyroscope Therapeutics logo
Category
Gyroscope Therapeutics is developing cutting edge, genetically defined therapies for the treatment of eye diseases linked to an unbalanced complement system, a part of the immune system. The Company was founded to capitalise on a convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery. Gyroscope’s lead product, GT005 (the FOCUS study), is a novel retinal gene therapy aimed at delivering a targeted, one-time treatment to genetically defined patients with advanced dry AMD. GT005 aims to restore the balance of a complement system known to be hyperactivated in AMD. An account of thisground-breaking treatment was the subject of a recent BBC News broadcast. Beyond GT005, Gyroscope is building a pipeline of gene therapy products for the treatment of eye diseases with high unmet medical need. Gyroscope is a private company headquartered in Stevenage, UK and is supported by experts in complement biology, AMD and gene therapy. Investors include Syncona Ltd., Cambridge Enterprise and Cambridge Innovation Capital. Further information can be found at www.gyroscopetx.com
Keywords:
0 results
Brought to you by PharmiWeb.com - Latest Jobs in Pharma